Warburg Pincus to invest Can$35 million in Protox to get BPH treatment to market
This article was originally published in Scrip
Warburg Pincus is to invest up to Can$35 million ($34 million) in publicly held Protox Therapeutics to provide the Canadian firm with the financial resources to pursue its lead programme, PRX302 for the treatment of benign prostatic hyperplasia (BPH), through to regulatory approval.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.